Off-the-Shelf immune cell therapy tested for stubborn lupus
NCT ID NCT06265220
Summary
This early-stage trial is testing a new cell therapy called AB-101 for adults with severe lupus or lupus-related kidney disease that hasn't improved with standard treatments. The therapy uses donated 'natural killer' immune cells, given alone or alongside antibody drugs, to try to better control the overactive immune system. The main goals are to see if the treatment is safe and shows signs of helping patients who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Artiva Investigational Site Aventura
Aventura, Florida, 33180, United States
-
Artiva Investigational Site Birmingham
Birmingham, Alabama, 35249, United States
-
Artiva Investigational Site Charlotte
Charlotte, North Carolina, 28625, United States
-
Artiva Investigational Site Iowa
Iowa City, Iowa, 52242, United States
-
Artiva Investigational Site Mesquite
Mesquite, Texas, 75150, United States
-
Artiva Investigational Site Plantation
Plantation, Florida, 33324, United States
-
Artiva Investigational Site San Diego
San Diego, California, 92121, United States
-
Artiva Investigational Site Tucson
Tucson, Arizona, 85724, United States
-
Artiva Investigational Site Woodlands
The Woodlands, Texas, 77382, United States
Conditions
Explore the condition pages connected to this study.